The United States has authorized a new material made with oyster mother-of-pearl to repair bone fractures

The United States has authorized a new material made with oyster mother-of-pearl to repair bone fractures

The product was developed by Australian researchers and uses waste from the pearl industry to obtain a compound that promotes bone tissue regeneration

Share:

The U.S. Food and Drug Administration (FDA) authorized the marketing of PearlBone Putty 1600, a bone graft substitute made from the nacre of pearl oysters, intended to promote the repair of fractures and fill defects in bones.

The authorization, granted on November 2 through the 510(k) regulatory process, represents a significant advancement for Marine Biomedical Ltd, a biotechnology company that emerged from research conducted at the University of Western Australia.

To manufacture the product, the company uses shells discarded by the pearl industry in Kimberley, a region located in the northwest of Australia.

How the material made from oyster nacre works

The scientific development is based on harnessing the natural properties of nacre, a mineralized substance found inside the shells of the oyster species Pinctada maxima.

While nacre is primarily composed of calcium carbonate, the mineral structure of human bones mainly contains calcium phosphates.

The researchers developed a chemical process that allows nacre to be transformed into a mineral compound compatible with bone tissue, called NCOC.

Minghao Zheng, a professor at the University of Western Australia and the scientific director of Marine Biomedical, led the research along with Rui Ruan.

“We found a way to accelerate a biomineralization process that took millions of years in nature,” Zheng explained.

The United States has authorized a new material made with oyster mother-of-pearl to repair bone fractures

The technique allows this transformation to be completed in approximately 24 hours. To achieve this, the shells are crushed and mixed with calcium phosphate and water until a moldable paste is obtained that hardens at the application site.

What results the researchers obtained

The results of the research were published in 2024 in the scientific journal Materials & Design.

During laboratory tests, the compound achieved a compressive strength of 10 megapascals, higher than that attributed by researchers to human trabecular bone.

Additionally, when the material came into contact with fluids similar to those in the body, it developed a surface of nanoporous apatite crystals, a mineral naturally present in bones and teeth.

The specialists also observed that the compound promoted the adhesion and proliferation of osteoblasts, the cells responsible for forming bone tissue.

In animal trials, the material showed superior repair results and biological compatibility compared to a conventional apatite substitute.

However, these results correspond to preclinical research and do not alone demonstrate therapeutic superiority in human patients.

An alternative to traditional bone grafts

Bone grafts are used in surgical interventions to fill spaces created by trauma, fractures, tumor removals, and other injuries.

One of the traditional alternatives involves extracting bone tissue from the patient themselves. However, this practice requires an additional procedure that can increase surgical time and cause complications.

PearlBone was designed to gradually degrade as new bone tissue forms.

The product is not intended to bear the mechanical loads of the skeleton on its own. When a fracture requires structural stability, the use of plates, screws, or other fixation devices may be necessary.

From industrial waste to a multimillion-dollar business

The patent for this technology was filed in 2018, while Marine Biomedical was established in 2021 and subsequently set up its manufacturing plant in Broome.

Rolee Kumar, the company's CEO, celebrated the decision of U.S. authorities.

“The FDA authorization is our ticket to the United States, the largest orthopedic market in the world”, she stated.

According to estimates released by the University of Western Australia, the U.S. market for bone grafts and substitutes is expected to reach USD 1.1 billion by 2026, with a projected annual growth rate of 6.2% until 2033.

After obtaining regulatory approval, Marine Biomedical will need to advance in the necessary commercial agreements to distribute the product in U.S. hospitals and clinics.